New Softgel Technologies

April 1, 2014

Catalent Pharma Solutions recently launched several new softgel product developments, all of which solve a delivery problem, while offering IP advantages to drug manufacturers.

New Softgel Technologies

Catalent Pharma Solutions recently launched several new softgel product developments, all of which solve a delivery problem, while offering IP advantages to drug manufacturers.

In 2014 Catalent will celebrate 80 years of softgel manufacturing and the company has recently launched several new softgel product developments, all of which solve a delivery problem, while offering IP advantages to drug manufacturers.

OptiGel Micro™, designed for prescription drug products, can accommodate a wide range of fill formulations and be sized from 1mm to 7mm in diameter, smaller than conventional capsules made using a rotary die.

Benefits include easier swallowing and capsule size can make compliance and adherence less daunting.

OptiGel Lock™, is designed to prevent the abuse of prescription pain medications, and the deliberate misuse of consumer pseudoephedrine products. Softgels cannot easily be ignited, ground or crushed into powders. For example, it can limit the amount of pseudoephedrine that can be extracted to use as a raw material for the manufacture of crystal meth.

OptiGel Bio™ enables macromolecules to be delivered orally and overcome permeability and stability challenges in a more easily administered form than intravenous injection.

OptiGel Bio may improve the permeability of large molecule APIs, while also enabling targeted delivery to be achieved via an enteric coating. This protective coating can also limit degradation of the API in the stomach. Patient advantages include fewer physician visits and less painful administration.

Company name: Catalent Pharma Solutions

Website: www.catalent.com

E-mail:

[email protected]